Infigratinib Active in Intrahepatic Cholangiocarcinoma

Angelica Welch
Published: Tuesday, Dec 18, 2018
Milind Javle, MD
Milind Javle, MD
The selective pan-FGFR kinase inhibitor infigratinib (BGJ398) showed meaningful antitumor activity and a manageable safety profile in patients with previously treated intrahepatic cholangiocarcinoma (IHC) who harbor FGFR2 fusions, according to updated phase II findings presented at the 2018 ESMO Congress.

“The next step here is to see whether we can expand this experience in the first-line setting, where this drug can be given upfront without chemotherapy. I believe that the efficacy will be seen in the first-line setting as well,” Javle suggested.
Javle M, Kelley RK, Roychowdhury S, et al. A phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor (TKI), in patients with previously-treated advanced cholangiocarcinoma containing FGFR2 fusions. In: Proceedings from the 2018 ESMO Congress; October 19-23, 2018; Munich, Germany. Abstract 3652.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x